ARAVAX
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment. Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.
ARAVAX
Social Links:
Industry:
Biotechnology Health Care Wellness
Founded:
2015-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.aravax.com.au
Total Employee:
11+
Status:
Active
Contact:
+610396570700
Email Addresses:
[email protected]
Total Funding:
42.2 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Content Delivery Network SSL By Default Mobile Non Scaleable Content HSTS Microsoft Exchange Online
Similar Organizations
iKOR Labs
iKOR Labs is a hemp product extract that protects the body from stress, improves recovery, and helps maintain a positive mental state.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
UbiVac
UbiVac is a clinical-stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer.
Current Employees Featured
Founder
Investors List
UniSuper
UniSuper investment in Series B - Aravax
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Aravax
Breakthrough Victoria
Breakthrough Victoria investment in Series B - Aravax
Agati Capital
Agati Capital investment in Series B - Aravax
Uniseed
Uniseed investment in Series B - Aravax
Tenmile
Tenmile investment in Series B - Aravax
Brandon Capital
Brandon Capital investment in Series B - Aravax
Medical Research Commercialisation Fund (MRCF)
Medical Research Commercialisation Fund (MRCF) investment in Seed Round - Aravax
Brandon Capital
Brandon Capital investment in Seed Round - Aravax
Official Site Inspections
http://www.aravax.com.au Semrush global rank: 11.51 M Semrush visits lastest month: 156
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Aravax"
Member profile: Aravax | BIA - bioindustry.org
Nov 14, 2024 Aravax applies proprietary technology and know-how to design highly targeted immunotherapies, which reset the immune system to tolerate a specific allergen without …See details»
Aravax - Overview, News & Similar companies | ZoomInfo.com
Aravax contact info: Phone number: +61 396570700 Website: www.aravax.com.au What does Aravax do? Aravax is a clinical stage biotechnology company focused on revolutionising the …See details»
Aravax - Crunchbase Company Profile & Funding
Contact Email [email protected]; Phone Number +610396570700; Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for …See details»
ARAVAX PTY LTD Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ARAVAX PTY LTD of MELBOURNE, VICTORIA. Get the latest business insights from Dun & Bradstreet.See details»
Aravax Pty Ltd Asset Profile | Preqin
Established in 2015 and based in Melbourne, Australia, Aravax Pty Ltd operates as a clinical-stage biotechnology company that is engaged in the development of a therapeutic drug to …See details»
Aravax Pty Ltd - Company Profile and News - Bloomberg Markets
Company profile page for Aravax Pty Ltd including stock price, company news, executives, board members, and contact informationSee details»
tackling peanut allergy from a new direction - business.gov.au
Nov 14, 2024 Aravax was founded in 2015 to refine and commercialise a new form of peptide immunotherapy developed by researchers at Alfred Health and Monash. Aravax has identified …See details»
Aravax - Monash Innovation
Aravax received the green light to proceed with Phase 2 trials of PVX108 2022. These trials commenced in adolescent patients with peanut allergy in Australia in 2023. The trial was then …See details»
Aravax - LinkedIn
Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the …See details»
Aravax Company Profile 2024: Valuation, Funding & Investors
Aravax General Information Description. Developer of peanut allergy vaccines designed to remove the risk of life-threatening reactions from peanuts. The company's vaccines are made …See details»
Aravax Company Profile - Office Locations, Competitors, Revenue …
Aravax has 5 employees at their 1 location. See insights on Aravax including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
$12m boost for peanut allergy treatment - Alfred Health
Jan 24, 2024 Minister for Economic Growth Tim Pallas has announced Breakthrough Victoria’s $12 million investment into Aravax as part of a $66 million funding round to develop the novel …See details»
Aravax is testing potential new ways to tackle food allergy
Nov 15, 2024 Aravax was founded in 2015 after research from Alfred Health and Monash University showed promise for a new type of peptide immunotherapy to potentially treat …See details»
Check Up: Aussie biotech Avarax on the verge of peanut allergy …
Feb 15, 2024 Take Aravax, a Melbourne-based biotech company developing the first safe, convenient, and disease-modifying treatment for peanut allergy. Aravax uses its proprietary …See details»
Aravax - peanut allergy - Monash University
Aravax are taking a peptide immunotherapy for peanut allergy vaccine to market. Research and trials have been performed in conjunction with Alfred Health, NHMRC, the Ilhan Food Allergy …See details»
Aravax Company Profile: Overview and Full News Analysis
Aravax utilizes proprietary platform technology to reset the immune system, enabling it to tolerate allergens without triggering severe reactions during treatment. The company has successfully …See details»
Peanut allergy treatment to ‘reset’ the immune system
May 19, 2017 The research has been supported by the Australian Food Allergy Foundation, Gandel Philanthropy, the Alfred Hospital Trust, and the National Health and Medical Research …See details»
Groundbreaking peanut allergy therapy - Food & Beverage …
Jan 25, 2024 Aravax is a clinical stage biotechnology company focused on revolutionising food allergy treatment through its product, PVX108. The immunotherapy uses synthetic peptides to …See details»
Aravax - Company Profile - Tracxn
Nov 4, 2024 Founded by Sara Prickett in the year 2015. Aravax has 200 competitors. Aravax - Developer of vaccine for peanut allergy. Raised a total funding of $92.7M over 4 rounds from 8 …See details»